<DOC>
	<DOCNO>NCT00661154</DOCNO>
	<brief_summary>To determine whether use radiolabelled analog 5-FU , [ 18F ] -5-fluorouracil , PET/CT image visually demonstrate differential chemotherapy delivery know tumor sit administration bevacizumab determine optimal time bevacizumab administration maximize chemotherapy delivery tumor improve cancer treatment .</brief_summary>
	<brief_title>Avastin/18-F-5-fluorouracil PET/CT Imaging Feasibility Project</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm adenocarcinoma colon . 2 . Patients must metastatic disease liver least one lesion measurable RECIST criterion within 4 week prior entry study 3 . Patients history colon adenocarcinoma treat surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval &gt; 5 year elapse primary surgery development metastatic disease . Clinicians consider biopsy lesion establish diagnosis metastatic colon adenocarcinoma substantial clinical ambiguity regard nature source apparent metastasis . 4 . Patients must ECOG performance status 02 5 . Patients must &gt; = 18 year age 6 . Laboratory value &lt; = 2 week prior enrollment : Absolute Neutrophil Count ( ANC ) &gt; = 1.5 x 10^9/L ( &gt; = 1500/mm^3 ) Platelets ( PLT ) &gt; = 100 x 10^9/L &gt; = 100,000/mm^3 ) Hemoglobin ( Hgb ) &gt; = 9 g/dL Serum creatinine &lt; = 1.5 ULN Serum bilirubin &lt; = 1.5 ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; = 3.0 x ULN ( &lt; = 5 x ULN liver metastasis present ) . Note : ERCP percutaneous stenting may use normalize liver function test . Negative proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary protein &lt; = 500 mg measure creatinine clearance ( CrCl ) &gt; = 50 mL/min 24hour urine collection 7 . Life expectancy &gt; = 12 week 8 . Ability give write informed consent accord local guideline 1 . Patients receive prior 5FU treatment metastatic colorectal adenocarcinoma exclude enrollment . Previous use 5FU adjuvant treatment resect stage II III colorectal adenocarcinoma allow , provide time last 5FU administration enrollment &gt; 3 month . 2 . Prior full field radiotherapy &lt; = 4 week limited field radiotherapy &lt; = 2 week prior enrollment . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease . 3 . Prior biologic immunotherapy &lt; = 2 week prior registration . Patients must recover therapyrelated toxicity 4 . Prior therapy antiVEGF agent 5 . Patients history another primary malignancy &lt; = 5 year , exception inactive basal squamous cell carcinoma skin 6 . Concurrent use investigational agent patient receive investigational drug &lt; = 4 week prior enrollment . 7 . Female patient pregnant breast feeding , adult reproductive potential employ effective method birth control . Barrier contraceptives must use throughout trial sex . Women childbearing potential must negative serum pregnancy test 48 hour prior administration study treatment . 8 . Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>